Get access to our best features
Get access to our best features
Published 3 years ago

EU seals deal with Novavax for up to 200 million COVID-19 vaccines

Summary by Ground News
Novavax has reached an agreement with the European Commission for the purchase of up to 200 million doses of NVX-CoV2373. The vaccine is the company's recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M™ adjuvant. Novavax is working to complete its rolling submission to the European Medicines Agency in the third quarter of 2021, with delivery of initial doses expected to begin following approval.

0 Articles

All
Left
Center
Right
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe
Ground News Article Assistant
Not enough coverage to generate an Article Assistant.

Bias Distribution

  • 46% of the sources are Center
48% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)